Scholarlink

<p>Cancer remains a major global health challenge characterized by uncontrolled cell proliferation. Despite the availability of various chemotherapeutic agents, such as cisplatin and sorafenib, the development of more effective and selective anticancer compounds is still required. In this study, a series of oxindole-based derivatives were synthesized and evaluated for their anticancer potential. The synthesized compounds were screened for in vitro cytotoxic activity, and several derivatives demonstrated promising results. Notably, compounds DH2 (IC₅₀ = 8.52 ± 2.35 µM), DH4 (6.42 ± 1.75 µM), DH5 (8.68 ± 3.15 µM), DH11 (6.42 ± 1.36 µM), DH13 (8.63 ± 1.45 µM), DH14 (7.73 ± 2.13 µM), DH20 (6.15 ± 1.35 µM), and DH21 (5.52 ± 1.12 µM) exhibited significant activity, comparable to the reference drug cisplatin (IC₅₀ = 5.65 ± 1.15 µM). Molecular docking studies were conducted to investigate the interaction of these compounds with target enzymes, revealing favorable binding affinities and key interactions responsible for their inhibitory activity. Structural characterization of all synthesized oxindole derivatives was confirmed using <sup>1</sup>H-NMR, <sup>13</sup>C-NMR and HREI-MS. Overall, the findings suggest that oxindole-based scaffolds represent a promising class of compounds for the development of novel anticancer agents.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synthesis of oxindole analogs as anticancer agents and their molecular docking studies

  • 期刊论文

  • 发表日期：

    2026年7月17日

查看全文
  • Muhammad Taha,
  • Dhary Alsahiji,
  • Firdos Alam Khan,
  • Fazal Rahim,
  • Muhammad Imran,
  • Muhammad Nawaz,
  • Nizam Uddin,
  • El Hassane Anouar,
  • Khalid Mohammed Khan

摘要

Cancer remains a major global health challenge characterized by uncontrolled cell proliferation. Despite the availability of various chemotherapeutic agents, such as cisplatin and sorafenib, the development of more effective and selective anticancer compounds is still required. In this study, a series of oxindole-based derivatives were synthesized and evaluated for their anticancer potential. The synthesized compounds were screened for in vitro cytotoxic activity, and several derivatives demonstrated promising results. Notably, compounds DH2 (IC₅₀ = 8.52 ± 2.35 µM), DH4 (6.42 ± 1.75 µM), DH5 (8.68 ± 3.15 µM), DH11 (6.42 ± 1.36 µM), DH13 (8.63 ± 1.45 µM), DH14 (7.73 ± 2.13 µM), DH20 (6.15 ± 1.35 µM), and DH21 (5.52 ± 1.12 µM) exhibited significant activity, comparable to the reference drug cisplatin (IC₅₀ = 5.65 ± 1.15 µM). Molecular docking studies were conducted to investigate the interaction of these compounds with target enzymes, revealing favorable binding affinities and key interactions responsible for their inhibitory activity. Structural characterization of all synthesized oxindole derivatives was confirmed using 1H-NMR, 13C-NMR and HREI-MS. Overall, the findings suggest that oxindole-based scaffolds represent a promising class of compounds for the development of novel anticancer agents.